-
-
-
-
Characteristic Total
n = 27EN group
n = 15LN group
n = 12P value Age, median (IQR)—y 64.0 (57.0–72.0) 63.0 (57.0–72.0) 65.0 (56.2–78.0) 0.581 Male sex—no. (%) 15 (55.5) 6 (40) 9 (75) 0.121 Coexisting chronic disease—no. (%) Hypertension 12 (44.4) 6 (40) 6 (50) 0.707 Coronary artery disease 2 (7.4) 1 (6.6) 1 (8.3) 1.000 Diabetes 2 (7.4) 1 (6.6) 1 (8.3) 1.000 Malignant tumor 3 (11.1) 2 (13.3) 1 (8.3) 1.000 Neurological disorders 6 (22.2) 3 (20) 3 (25) 1.000 Chronic kidney disease 1 (3.7) 0 1 (8.3) HIV/AIDS 2 (7.4) 0 2 (16.6) Chronic liver disease 2 (7.4) 0 1 (8.3) Laboratory tests before transfusion White-cell count, median (IQR)—(× 10−9/L) 5.37 (4.81–7.99) 6.49 (4.81–7.99) 4.16(3.31–7.47) 0.075 Neutrophil count, median (IQR)—(× 10−9/L) 3.57 (2.58–5.58) 4.25 (2.94–5.70) 2.83(1.91–4.26) 0.083 Lymphocyte count, median (IQR)—(× 10−9/L) 1.24 (0.62–1.85) 1.44 (0.46–1.85) 1.07 (0.64–1.33) 0.614 Platelet count, median (IQR)—(× 10−9/L) 175 (137–194) 185 (163–219) 148 (78–183) 0.054 Hematocrit, median (IQR)—(%) 33.4 (28.4–38.4) 33.4 (26.4–40.1) 34.1 (28.7–38.3) 0.943 Serum creatinine, median (IQR)—(μmol/L) 69.1 (57.4–75.0) 66.0 (56.0–75.0) 70.5 (59.0–112.0) 0.683 Total bilirubin, median (IQR)—(μmol/L) 11.4 (8.6–18.0) 11.9 (9.4–18.0) 10.8(8.1–20.0) 0.648 Alanine aminotransferase, median (IQR)— (U/L) 17.0 (10.0-28.0) 24.0 (13.0–33.0) 13.0 (8.5–26.0) 0.103 Aspartate aminotransferase, median (IQR)—(U/L) 26.0 (20.0–42.0.0) 27.0 (21.0–60.0) 24.5 (15.5–34.5) 0.516 High-sensitivity C-reactive protein, median (IQR)—(mg/L) 3.1 (0.8–37.8) 3.1 (0.8–38.1) 3.9 (0.7–42.8) 0.733 Table 1. Demographic and clinical characteristics of patient before CP therapy.
-
Characteristic Total
n = 27EN group
n = 15LN group
n = 12P value Interval between symptom onset and transfusion, median (IQR)—d 45.0 (35.0–49.0) 40.0 (26.0–47.0) 45.5 (41.2–57.0) 0.075 Interval between symptom onset and last positive test before CP therapy, median (IQR)—d 44.0 (30.0–47.0) 39.0 (24.0–45.0) 44.5 (38.2–54.7) 0.126 Body temperature, median (IQR)—℃ 36.9 (36.6–37.0) 36.8 (36.5–37.2) 36.9 (36.7–37.0) 0.516 Fever—no. (%) 6 (22.2) 4 (26.6) 2 (16.6) 0.662 Oxygen therapy—no. (%) No oxygen treatment 19 (70.3) 10 (66.6) 9 (75.0) 0.696 Nasal catheter oxygen therapy 3 (11.1) 3 (20) 0 (0) Mechanical ventilation 5 (18.5) 2 (13.3) 3 (25.0) 1.000 Extracorporeal membrane oxygenation 1 (3.7) 1 (6.6) 0 (0) Fraction of inspiration O2 (n = 26), median (IQR)—% 21.0 (21.0–33.0) 21.0 (21.0–33.0) 21.0 (21.0–35.2) 0.809 Respiratory rate > 24 times/min—no. (%) 5 (18.5) 3 (20) 2 (16.6) 1.000 Peripheral oxygen saturation, median (IQR)—% 98.0 (97.0–99.0) 97.0 (97.0–99.0) 97.0 (97.0–98.5) 0.905 Vasopressors—no. (%) 4 (14.8) 1 (6.6) 3 (25.0) 0.294 Anti-virus therapy—no. (%) Ribavirin 4 (14.8) 2 (13.3) 2 (16.6) 1.000 Lopinavir 8 (29.6) 3 (20.0) 5 (41.6) 0.398 Favipiravir 2 (7.4) 2 (13.3) 0 (0) Definite or suspected coinfection—no. (%) 6 (22.2) 3 (20.0) 3 (25.0) 0.433 Broad-spectrum antibiotic therapy—no. (%) 15 (55.5) 8 (53.3) 7 (58.3) 1.000 Corticoid therapy—no. (%) 5 (18.5) 3 (20) 2 (16.6) 1.000 Immunoglobulin therapy—no. (%) 6 (22.2) 4 (26.6) 2 (16.6) 0.662 Table 2. Patients' status and treatments received before CP therapy.
-
Characteristic Total
n = 27EN group
n = 15LN group
n = 12P value Total volume dose of CP, median (IQR)—mL 400 (200–600) 400 (200–400) 400 (400–800) 0.861 Transfusion-related adverse reactions—no. (%) 0 (0) 0 (0) 0 (0) Interval between first transfusion and discharge, median (IQR)—d 11.0 (6.0–25.0) 7.0 (4.0–11.0) 24.0 (14.7–28.7) Pulmonary imaging improvement 15/20 7/8 8/12 0.603 Length of hospital stay, median (IQR)—d 43.0 (24.0–54.0) 37.0 (19.0–50.0) 52.0 (35.0–63.7) Mortality of 60 days—no. (%) 3 (11.1) 0 (0) 3 (25) Table 3. Patients' status after transfusion and outcome after CP therapy.
Figure 3 个
Table 3 个